EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 704 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... December 6, 2019 FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... December 7, 2021 Can I Have a Nonviolent Relationship with Cancer? (Part 1) November 15, 2021 Joining the dots: How our new research data strategy will unlock... July 7, 2022 Load more HOT NEWS 20 years of Cancer Research UK: Celebrating our research nurses How to Make a Homemade Face Mask from a Folded Scarf—No... Why People With Cancer Need to Be Taking Care of Their... Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe...
